Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free SSRI antidepressant cases. Here at Leading Justice, we can personally customize your firm’s SSRI advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of SSRI antidepressant advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reevaluated to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to birth defects and SSRI antidepressants, Leading Justice will increase your firm’s SSRI case load. If you are interested in helping victims of alleged SSRI birth defects, our vast consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence to allocate your full budget, and rest easy knowing your money is being used in the best way possible.
Every law firm we work with at Leading Justice has a direct impact on how we classify claims as qualified or not. While our extensive experience working alongside plaintiff law firms enables us to recognize a great case when we see one, we will customize our SSRI antidepressant case intake specifications to the exact criteria you are seeking. So, if your firm has certain SSRI antidepressant qualifying case criteria you would like us to use, we will train our intake specialists to apply this criteria to every call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of SSRI data with zero chance of fraud.
Our Take on SSRI Antidepressant Drugs
Although SSRIs (selective serotonin reuptake inhibitors) like Paxil, Zoloft, Celexa, Prozac, Wellbutrin and Lexapro are the most commonly prescribed antidepressant drugs on the market, research shows that babies born to women who took an SSRI while pregnant may have an increased risk of developing serious birth defects. Among these alleged SSRI birth defects are spina bifida, heart defects, neural tube defects, cleft lip, cleft palate and even autism – all of which can severely impact an affected baby’s quality of life in the future. As a result, many SSRI antidepressant drugs have been classified by the FDA as pregnancy category C or D medications, which means they have the potential to cause serious fetal harm when taken by pregnant women.
According to national statistics, SSRI antidepressant drugs have been used by up to one in six women of childbearing age, potentially putting them at risk of giving birth to a baby with severe and possibly even fatal birth defects. In a New England Journal of Medicine study published in 2006, researchers found a shocking six-times increased risk of the life-threatening birth defect PPHN (persistent pulmonary hypertension of the newborn) in babies exposed to an SSRI antidepressant after the 20th week of pregnancy. SSRI drug makers have already paid out billions of dollars in birth defect settlements, and many more settlement agreements and jury awards are expected in future SSRI antidepressant litigation.